Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026

Source Summary

MILAN, Italy, July 7, 2026 – Italfarmaco S.p.A. today announced the presentation of new data from its clinical development programme for givinostat in patients with Duchenne muscular dystrophy (DMD) at the 19 th International Congress on Neuromuscular Diseases (ICNMD) 2026, taking place from July 7-11 in Florence, Italy. The presentations highlight findings from the pivotal Phase 3 EPIDYS trial and its ongoing open-label extension (OLE) study, including quantitative magnetic resonance imaging (MRI) data and insights into long-term loss-of-ambulation (LoA) and safety. "These analyses contribute to the growing body of evidence on givinostat in DMD,” said Scott Baver, Ph.D., VP, Head of Global Medical Affairs, Rare Diseases, Italfarmaco . “The MRI findings and long-term observational data provide additional insights into disease progression and treatment outcomes in this patient population." Key findings: